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Abstract
Rationale:The effecicacy of rehabilitation therapy for aphasia caused by stroke is uncertain.
Aims and Hypothesis: The Very Early Rehabilitation of Speech (VERSE) trial aims to determine if
intensive prescribed aphasia therapy (VERSE) is more effective and cost saving than nonprescribed, intensive (Usual Care-Plus) and non-intensive usual care (UC) therapy when started
within 15 days of stroke onset and continued daily over four weeks. We hypothesise that
aphasia therapy when started very early after stroke and delivered daily could enhance
recovery of communication compared with usual care.
Sample size estimates: 246 participants (82 per arm) will provide 80% power to detect a 4.4%
improvement on AQ between VERSE and UC plus at a significance level of α = 0.05.
Methods and design: Setting: Acute-care hospitals and accompanying rehabilitation services
throughout Australia, 2014-2017.
Design: Prospective, randomised, paralell group, open-label, blinded endpoint assessment
(PROBE) trial.
Participants: acute stroke in previous 14 days and aphasia diagnosed by Aphasia Quotient (AQ)
of the Western Aphasia Battery (WAB).
Randomisation: Computer-generated blocked and stratified randomisation procedure by
aphasia severity according to WAB, to one of three arms.
Intervention: All participants receive Usual care (UC) - usual ward based aphasia therapy. Arms
2 and 3 receive a total of twenty additional sessions (45-60 minutes, provided daily) of aphasia
therapy. Arm 1: Usual Care (UC) - (no additional therapy); Arm 2: UC-Plus usual ward based
therapy; Arm 3: VERSE therapy - a prescribed and structured aphasia therapy program. The
additional intervention must be provided before day 50 post stroke.
Study outcome measures: the AQ of WAB at 12 weeks post-stroke. Secondary outcomes include
discourse measures, the Stroke and Aphasia Quality of Life Scale-39 (SAQoL-39) and the
Aphasia Depression Rating Scale (ADRS) at 12 and 26 weeks. Economic evaluation: Incremental
cost-effectiveness ratios at 26 weeks will be reported.
Discussion: This trial is designed to test whether the intensive and prescribed VERSE
intervention is effective in promoting maximum recovery and preventing costly health
complications in a vulnerable population of survivorsof stroke. It will also provide novel,
prospective, aphasia specific cost-effectiveness data to guide future policy development for this
population.

Introduction and Rationale
Aphasia affects approximately a third of the 440,000 individuals living with stroke in Australia
[1]. Recovery from aphasia is highly variable with multiple factors believed to contribute to the
overall extent of communication recovery achieved by each individual[2]. There are currently
few available specific medical treatments designed to reduce the impacts of aphasia occurring
as a consequence of stroke, therefore aphasia rehabilitation is the mainstay of recovery for
people with aphasia.
Early aphasia rehabilitation is thought to enhance the natural processes of spontaneous
recovery by strengthening neural networks through the use of highly repetitious, task-specific
behaviours that require coinciding neuronal firing of a group of connected neurons[3]. These
behaviours are believed to minimise independent neuronal activation that may produce
maladaptive behaviours[3].
The 2012 Cochrane Review examined 39 trials of aphasia therapy following stroke and found no
Level 1 evidence[4] for the efficacy of aphasia treatments in the long-term. There was some
evidence that speech and language therapy (SLT) was more effective than no SLT however
caution is required when interpreting the Cochrane Review[4] results as many studies were
comparative in nature, lacked adherence to the CONSORT statement[5] and demonstrated
inferior design quality[4]. Additionally, little is known about the costs of available treatment
options.
Aims and Hypotheses
VERSE aims to determine if intensive aphasia therapy provides greater efficacy and is at least
cost-effective when compared to usual ward based rehabilitation (UC) at 12 weeks post stroke,
when therapy is commenced within the first fifteen days post stroke. Aphasia therapy in this
trial refers to direct impairment-based aphasia treatment in contrast to other communication
therapy, case-management, patient/family counselling and education.
Our primary hypothesis is that compared to UC, early intensive aphasia therapy will result in
improved communication ability, determined by at least a 20% greater score on the (AQ) of the
(WAB)[6] at 12 weeks post stroke.
Secondary hypotheses:
i) VERSE aphasia therapy will result in a 4.4% greater score on the AQ when compared to
UC-Plus aphasia therapy at 12 and 26 weeks post stroke.
ii) Very early intensive aphasia therapy will result in better quality of life using SAQol – 39 at
12 and 26 weeks post stroke than UC control.
iii) Very early intensive aphasia therapy will be more cost-effective than UC at 26 weeks
post stroke.
VERSE is a three-armed prospective, single-blinded multicentre, randomised controlled trial
with primary outcome 12 weeks and follow-up at 26 weeks post-stroke (see Figure 1) and
intention to treat analysis.
Patient Population

Approximately 16 acute care hospitals and related rehabilitation services in Australia and New
Zealand will be involved. Participants include acute stroke patients (>18 years) with aphasia (AQ
score <93.7) who are otherwise medically stable, who provide consent, and are assessed and
randomised by the baseline assessor within 14 days of stroke. See Table 1 for inclusion and
exclusion criteria.
Methods
The intervention is provided by qualified and trained speech pathologists for a maximum of 25
working days, commencing the day after baseline assessment and randomisation (see Figure 2).
Participants and families in addition to staff not involved in providing the intervention to
participants are blinded to group allocation.
Randomisation
Participants are stratified by baseline aphasia severity, (AQ scores mild: 62.6 – 93.7, Moderate:
31.3 – 62.5 and severe: 0 – 31.2) and then randomised to one of three groups. The
randomisation schedule was created by an independent statistician, using a computergenerated permuted blocked procedure and allocation ratio of 1:1:1. Participants are
randomise via a web based electronic data collection system. (REDCapTM)[7].
Intervention
ARM 1: Usual Care (UC)
Participants will receive usual care alone. UC speech pathologists will be responsible for all
speech pathology services including case management, education, counselling and any cooccurring dysphagia management for all trial participants. We have anticipated the intensity of
UC direct aphasia therapy to be less than 6 hours in total based on our previous work [6,8].
ARM 2: Usual Care – Plus (UC-Plus)
In addition to usual care, the UC-Plus group will receive aphasia therapy that is determined by
the treating therapist; at the prescribed regimen:
(a) between 45-60 minutes of 1:1 therapy 5 days per week for 20 sessions (15-20 hours) (within
a maximum of 25 working days)
(b) a minimum of 3 and a maximum of 5 sessions per week

ARM 3: VERSE Therapy
The VERSE aphasia therapy intensity and timing of commencement of intervention will match
the UC-Plus group however the VERSE treatment is prescribed by an Intervention Protocol
provided only to the trained VERSE therapists and is designed for all aphasia types and severity
levels.
Therapists complete a daily therapy log in an electronic Case Report Form (eCRF) REDCap[7] for
each participant including content, duration and frequency of all therapy sessions. UC-Plus and
VERSE sessions will be video recorded, monitored and cross-referenced with information
provided in the eCRF. Deviations from the VERSE protocol will be addressed with the clinician.

Required study assessments and the assessment timeline are outlined in Table 2.
All outcome assessments will be carried out by qualified and study trained speech pathologists
who are independent blinded assessors. Information relating to resource utilisation will be
obtained from the participant.
Participants will be assessed for adverse events (AEs) throughout this trial. All AEs reported
during the intervention period (between consent and 50 days post stroke), will be reported.
AEs that relate to the new diagnosis or worsening of clinical depression will be reported up to
week 26.
AEs that meet the criteria for serious,(SAEs) will be reported for the duration of the project.
Trial therapists and blinded assessors staff will identify and report events and reviewed by a
medical monitor and independent Data Safety Monitoring Committee.
Primary Outcome
The primary outcome is the AQ score of the WAB assessed by a blinded assessor at 12 weeks
post stroke. The WAB is considered a reliable measure of severity of language impairment and
is sensitive to change [6].
Secondary Outcomes
These are assessed by a blinded assessor and include;
Health related Quality of life as determined by SAQoL- 39[10] at 12 and 26 weeks
Resource Utilisation at 26 weeks. Participant provided services will be collected at 12 and 26
weeks by the blinded assessor. Information will be used to estimate the cost effectiveness of
VERSE therapy compared to UC and UC-plus. Amount and type of inpatient and outpatient
rehabilitation, length of acute hospital stay, discharge destination, hospital readmissions,
general practitioner visits, community and health care service use, medication use, respite and
informal care services and any speech and communication aids/devices changes in employment
status and services utilised as a result of the stroke will be collected.
Sample Size
A sample of 246 participants will provide 80% power to detect this difference at a (two-tailed)
significance level of α = 0.05, after adjusting for 5% non-adherence and a loss to analysis of 12%
(due to death and dropout).
Statistical Analysis
An intention-to-treat analysis will be used. A secondary per protocol analysis will explore dose
related differences in the primary outcome.
Primary analysis
This will be a between-group comparison of recovery on AQ at 12 weeks. A generalized
estimating equations model will be developed to analyse difference in recovery between
groups. Differences in baseline AQ scores and baseline National Institute of Health Stroke Scale

(NIHSS)[8] will be included as covariates in the model. The intervention effect will be
represented as the difference in percent of maximal potential recovery achieved.
Secondary analyses
The generalised estimating equations model developed for the primary analysis will also
examine differences in recovery on AQ between the three groups (VERSE, UC-plus and UC) and
to assess whether these differences are sustained at 26 weeks.
A generalized estimating equations model will be developed to analyse differences between
the three groups (VERSE, UC-Plus and UC) in recovery of connected speech (Discourse
measures) at 12 weeks and 26 weeks. Baseline AQ scores and baseline modified Rankin
Score[9], will be controlled for by including these as covariates in the model. The intervention
effect will be represented as the difference in amount of connected speech.
A generalized estimating equations model will be used to determine the effect of intervention
group on Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)[10] scores at 12 and 26 weeks
post-stroke, adjusting for known confounding variables (e.g. age, gender, NIHSS[8], mRS[9]).
Resource utilisation will be captured using a standardised approach from a societal perspective
with the main focus on the health sector. This will include out-of-pocket costs to patients and
family members and workforce impacts. Incremental cost-effectiveness ratios will be reported
as costs per unit improvement in AQ-score and per occurrence of depression (medically
diagnosed and treated and/or an ADRS score of 9 and above) avoided at 26 weeks post stroke.
Societal perspective costs will include government as third party payer, costs to patients and
carers/family members and limited costs to other sectors. Probabilistic multivariable analysis
will be conducted to account for variability around the point estimates and results will be
reported as medians (95% uncertainty intervals) using @RISK software (Palisade
Corporation)[11].
Discussion
This trial is designed to test whether the intensive and prescribed VERSE intervention is
effective in promoting maximum recovery and preventing costly health complications in a
vulnerable population of survivors of stroke. It will also provide novel, prospective, aphasia
specific cost-effectiveness data which may be used to improve resource allocation and policy
development in acute and subacute hospital settings for very early aphasia intervention. Since
the trial commenced recruitment, 81 patients have been enrolled from 11 hospitals.
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Figure 1
CONSORT Flow diagram of the VERSE trial.

VERSE

Table 1. Eligibility criteria

Inclusion criteria
Patients over the age of 18 with acute stroke and resultant acute aphasia of any type (ICD10 codes 161 – 164 i.e. no TIA, SAH or SDH)
A score of less than 93.7 of the Aphasia Quotient
Patients who are deemed medically stable at recruitment
Patients with the ability to maintain a wakeful alert state for 30 consecutive minutes within
14 days of stroke onset
Patients with normal or corrected hearing and vision
Patients with informed consent obtained by participant or person responsible
Exclusion criteria
Patients will be excluded from the study if they have any of the following:
Pre existing aphasia at the time of enrolment
Patients who have suffered a head injury, have had or require neurosurgery. (Clot retrieval
surgery is not an exclusion if patient is stable post operatively and meets the above
criteria)
Pre existing clinical diagnosis of dementia
Clinical diagnosis or treatment of major depression at time of enrolment
Concurrent progressive neurological disorders
Patients unable to participate in English based therapy due to English being a second
language.
Participation in other intervention trials without prior approval from VERSE trial manager.

Table 2. Schedule of assessment

Assessment

Baseline

Treatment

Between Day 2
and Day 14 post
stroke

Day after
Baseline (4-5
weeks)

Screening/Eligibility

X1

Frenchay Aphasia Screening test
(FAST) [12]

X1

Consent

X1

Western Aphasia Battery (AQ)[6]

X2

Randomisation

X1

Demographics

X1

Past medical History

X1

NIHSS[8]

X1

mRS[9]

X1

RBHOMB[13]

X1

Oxfordshire Classification

X1

Follow up post stroke
Week 12

Week 26

12 weeks (+/- 7 days)

26 weeks (+/- 7 days)

X5

X5#

(OCSP)[14]
Clock Drawing/Cog test[10]

X1

Boston Naming Test (BNT)[15]

X2

X5#

X5#

Discourse collection[16]

X2

X5#

X5#

Stroke and Aphasia Quality of life
Scale (SAQoL-39)[10]

X5#

X5#

Aphasia Depression Rating Scale
[17]

X5#

X5#

Resource Utilisation

X5

X5

X3 or 4

Intervention and recording of
therapy

Patient diary provided

X3 or 4**

X5

Adverse Events

X3

X5

X5

X3

X5

X5

Serious Adverse Events
1

X = person screening and enrolling the subject. May be X
X2 = Trained speech pathologist
X3 = Usual care speech pathologist (UC and UC Plus)
X4 = VERSE therapist

2

X5= Blinded Assessor
** Diary provided on last day of therapy with treating speech pathologist. This may be on discharge from the acute
ward or as late as Day 50.
#

Secondary outcome measure

